Citi lowered the firm’s price target on Akero Therapeutics (AKRO) to $78 from $80 and keeps a Buy rating on the shares. The company reported Q1 earnings after it revealed clinical data from its Phase 2b SYMMETRY trial at the European Association for the Study of the Liver conference last week, the analyst tells investors in a research note. The firm says the detailed data showed that efruxifermin treatment led to improvements on multiple noninvasive measures of liver fibrosis, adding on to 96-week topline liver biopsy data released earlier this year.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics Advances in MASH Treatment Research
- Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
- Akero Therapeutics: Strong Financial Health and Promising Clinical Data Justify Buy Rating
- Akero Therapeutics reports Q1 EPS (90c), consensus (99c)
- Akero Therapeutics sees cash, equivalents funding operating plan into 2028